Insmed Inc (INSM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Insmed Inc stock (INSM) is currently trading at $148.31. Insmed Inc PS ratio (Price-to-Sales) is 49.46. Analyst consensus price target for INSM is $212.21. WallStSmart rates INSM as Sell.
- INSM PE ratio analysis and historical PE chart
- INSM PS ratio (Price-to-Sales) history and trend
- INSM intrinsic value — DCF, Graham Number, EPV models
- INSM stock price prediction 2025 2026 2027 2028 2029 2030
- INSM fair value vs current price
- INSM insider transactions and insider buying
- Is INSM undervalued or overvalued?
- Insmed Inc financial analysis — revenue, earnings, cash flow
- INSM Piotroski F-Score and Altman Z-Score
- INSM analyst price target and Smart Rating
Insmed Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Insmed Inc (INSM) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, revenue growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Insmed Inc (INSM) Key Strengths (4)
Revenue surging 152.60% year-over-year
102.67% of shares held by major funds and institutions
Large-cap company with substantial market presence
Good growth relative to its price
Supporting Valuation Data
Insmed Inc (INSM) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 49.5x annual revenue
Very expensive at 39.7x book value
Supporting Valuation Data
Insmed Inc (INSM) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (1.09) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 152.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (49.46), Price/Book (39.67) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -249.30%, Operating Margin at -94.60%, Profit Margin at -210.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -249.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 152.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
INSM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
INSM's Price-to-Sales ratio of 49.46x trades 102% above its historical average of 24.49x (86th percentile), historically expensive. The current valuation is 51% below its historical high of 100.37x set in May 2013, and 12265% above its historical low of 0.4x in Oct 2008.
WallStSmart Analysis Synopsis
Data-driven financial summary for Insmed Inc (INSM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Insmed Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 606M with 153% growth year-over-year. The company is currently unprofitable, posting a -210.5% profit margin.
Key Findings
Revenue growing at 153% YoY, reaching 606M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 42% of revenue (255M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -210.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -294M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Insmed Inc maintain 153%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Insmed Inc.
Bottom Line
Insmed Inc is a high-conviction growth story with revenue accelerating at 153% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -210.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Insmed Inc(INSM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.